[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555051":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":91,"collaborators":93,"id":97,"slug":32,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":98,"sex":104,"minAge":105,"maxAge":32,"enrollmentInfo":106,"targetDuration":32,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":46,"whyStopped":32,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Chang Gung Memorial Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Immediate Long-Acting Injectable Treatment Group","EXPERIMENTAL","Immediate switch to long-acting injectable antiretrovirals on enrollment",[13],"Drug: cabotegravir\u002Frilpivirine (600mg\u002F 900mg)",{"label":15,"type":16,"description":17,"interventionNames":18},"Delayed Long-Acting Injectable Treatment Group","ACTIVE_COMPARATOR","Keep on standard all-oral antiretrovirals on enrollment for 24 weeks, then switch to long-acting injectable antiretrovirals",[19],"Drug: Antiretroviral Combinations",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","cabotegravir\u002Frilpivirine (600mg\u002F 900mg)","Immediate switch from oral antiretroviral to long-acting injectables",[9],[27],"Cabenuva",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Antiretroviral Combinations","Standard all-oral antiretroviral combinations",[15],null,[34],{"name":35,"affiliation":5,"role":36},"Nan-Yu Chen, MD, PhD","PRINCIPAL_INVESTIGATOR",[38],{"name":35,"role":39,"phone":40,"phoneExt":41,"email":42},"CONTACT","+886 3 3281200","8450","nanyuchen@cgmh.org.tw",[44,59,70,83],{"facility":45,"status":46,"city":47,"state":32,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Chang Gung Memorial Hospital, Keelung","RECRUITING","Keelung","204","Taiwan",{"type":51,"coordinates":52},"Point",[53,54],121.74094,25.13089,{"lat":54,"lon":53},[57],{"name":58,"role":39,"phone":32,"phoneExt":32,"email":42},"Nan-Yu Chen",{"facility":60,"status":46,"city":61,"state":32,"zip":62,"country":49,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"Chang Gung Memorial Hospital, Taipei","Taipei","105",{"type":51,"coordinates":64},[65,66],121.52639,25.05306,{"lat":66,"lon":65},[69],{"name":58,"role":39,"phone":32,"phoneExt":32,"email":42},{"facility":71,"status":46,"city":72,"state":32,"zip":73,"country":49,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Taoyuan General Hospital, Ministry of Health and Welfare","Taoyuan","330",{"type":51,"coordinates":75},[76,77],121.29696,24.99368,{"lat":77,"lon":76},[80],{"name":81,"role":39,"phone":32,"phoneExt":32,"email":82},"Chien-Yu Cheng, MD, PhD","s841060@gm.ym.edu.tw",{"facility":84,"status":46,"city":72,"state":32,"zip":85,"country":49,"cosmosGeoPoint":86,"geoPoint":88,"contacts":89},"Chang Gung Memorial Hospital, Linkou","333",{"type":51,"coordinates":87},[76,77],{"lat":77,"lon":76},[90],{"name":58,"role":39,"phone":40,"phoneExt":41,"email":42},{"type":92,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[94],{"name":95,"class":96},"Taoyuan General Hospital","OTHER_GOV","100555051",false,"NCT06507059","Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals","A Phase 3 Study Comparing Clinical Outcomes in People Living With HIV (PLHIV) With Suboptimal Adherence Treated With Injectable Long-acting Antiretrovirals Versus Oral Antiretrovirals","SUPLA","Inclusion Criteria:\n\n* Willing to sign the written informed consent form for male and female participants aged 18 and above.\n* At the time of enrollment, diagnosed with HIV infection for a minimum of 12 months.\n* Under oral antiretroviral treatment (ART), which can be irregular or interrupted, with the most recent viral load ≥ 200 copies\u002FmL.\n* Body weight ≥ 35Kg.\n* Willing to maintain contact with the research team throughout the study (provide accurate and reachable phone numbers, social accounts like Line, or reliable contact information of family or friends).\n* Willing to receive gluteal (buttocks) drug injections.\n* Willing to transition back to oral medication or follow the recommended treatment prescription according to the then-current national treatment guidelines after discontinuation of long-acting injectable drugs.\n\nExclusion Criteria:\n\n* For those currently undergoing oral antiretroviral therapy, who have started or restarted oral ART for less than six consecutive months before screening.\n* Previously undergone HIV drug resistance testing and known to have resistance mutations to either cabotegravir or rilpivirine.\n* Unable to commit to maintaining contact with the research team throughout the study.\n* Individuals who cannot receive treatment for hepatitis B during the period of transitioning to long-acting injections, if they are hepatitis B carriers.\n* Individuals with buttock fillers.\n* Women who are planning to become pregnant, pregnant, or currently breastfeeding.","ALL","18 Years",{"count":107,"type":108},40,"ESTIMATED","INTERVENTIONAL",[111],"PHASE3","This study aims to determine whether people living with HIV (PLHIV) with suboptimal medical adherence can achieve better viral suppression with long-acting antiretrovirals (LA) compared to all-oral antiretrovirals.",[114,115],"HIV-1-infection","Non-Adherence, Medication",[117],"HIV-1, non-adherence","2024-08-21",{"date":120,"type":121},"2024-08-23","ACTUAL",{"date":123,"type":121},"2024-07-19",{"date":125,"type":108},"2026-12-31",{"name":5,"class":6},4]